DK2739621T3 - Krystaller med 2-acylaminothiazolforbindelse - Google Patents
Krystaller med 2-acylaminothiazolforbindelse Download PDFInfo
- Publication number
- DK2739621T3 DK2739621T3 DK12759833.2T DK12759833T DK2739621T3 DK 2739621 T3 DK2739621 T3 DK 2739621T3 DK 12759833 T DK12759833 T DK 12759833T DK 2739621 T3 DK2739621 T3 DK 2739621T3
- Authority
- DK
- Denmark
- Prior art keywords
- degree
- compound
- maleic acid
- acid salt
- crystal
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Claims (7)
1. Krystal af l-(3-chlor-5-{[4-(4-chlorthiophen-2-yl)-5-(4-cyclohexylpiperazin-l-yl)thiazol-2-yl]carbamoyl}pyridin-2-yl)piperidin-4-carboxylsyre-maleinsyresalt, hvor de endoterme peak-temperaturer i differentiel scanningskalorimeteranalyse er mellem 229 og 232 grader C, og mellem 300 og 303 grader C.
2. Krystal af l-(3-chlor-5-{[4-(4-chlorthiophen-2-yl)-5-(4-cyclohexylpiperazin-l-yl)thiazol-2-yl]carbamoyl}pyridin-2-yl)piperidin-4-carboxylsyre-maleinsyresalt, der har peaks i pulverrøntgenkrystalanalyse ved anvendelse af en Cu-K-alfastråle ved 8,5 grader, 9,5 grader, 12,1 grader, 20,4 grader, 22,7 grader og 23,3 grader for en brydningsvinkel på 2-theta.
3. Krystal ifølge krav 2, der har endoterme peak-temperaturer i differentiel scanningskalorimeteranalyse på 229 til 232 grader C, og 300 til 303 grader C.
4. Farmaceutisk sammensætning, der omfatter krystallet ifølge et hvilket som helst af kravene 1 til 3 og en farmaceutisk acceptabel excipiens.
5. Farmaceutisk sammensætning ifølge krav 4, der er en farmaceutisk sammensætning til forebyggelse eller behandling af thrombocytopeni.
6. Anvendelse af et krystal ifølge et hvilket som helst af kravene 1 til 3 til fremstilling af cn farmaceutisk sammensætning til forebyggelse eller behandling af thrombocytopeni.
7. Krystal ifølge et hvilket som helst af kravene 1 til 3 til forebyggelse eller behandling af thrombocytopeni.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011169730A JP2014144916A (ja) | 2011-08-03 | 2011-08-03 | ２−アシルアミノチアゾール化合物の結晶 |
| PCT/JP2012/004885 WO2013018362A1 (en) | 2011-08-03 | 2012-08-01 | 2-acylaminothiazole compound crystals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2739621T3 true DK2739621T3 (da) | 2017-09-04 |
Family
ID=46875935
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12759833.2T DK2739621T3 (da) | 2011-08-03 | 2012-08-01 | Krystaller med 2-acylaminothiazolforbindelse |
| DK17176670.2T DK3246325T3 (da) | 2011-08-03 | 2012-08-01 | Krystaller af en 2-acylaminothiazol-forbindelse |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17176670.2T DK3246325T3 (da) | 2011-08-03 | 2012-08-01 | Krystaller af en 2-acylaminothiazol-forbindelse |
Country Status (15)
| Country | Link |
|---|---|
| EP (2) | EP2739621B1 (da) |
| JP (1) | JP2014144916A (da) |
| CY (2) | CY1120647T1 (da) |
| DK (2) | DK2739621T3 (da) |
| ES (2) | ES2636749T3 (da) |
| HR (2) | HRP20171214T1 (da) |
| HU (1) | HUE034270T2 (da) |
| LT (3) | LT2739621T (da) |
| NO (1) | NO2020032I1 (da) |
| PL (2) | PL2739621T3 (da) |
| PT (2) | PT2739621T (da) |
| RS (1) | RS60358B1 (da) |
| SI (2) | SI3246325T1 (da) |
| SM (1) | SMT202000173T1 (da) |
| WO (1) | WO2013018362A1 (da) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2764866A1 (en) | 2013-02-07 | 2014-08-13 | IP Gesellschaft für Management mbH | Inhibitors of nedd8-activating enzyme |
| CN106749226B (zh) * | 2017-03-15 | 2019-12-20 | 广东赛拓医药科技有限公司 | 一种avatrombopag马来酸盐晶型C的制备方法 |
| WO2020044364A1 (en) | 2018-08-27 | 2020-03-05 | Mylan Laboratories Limited | Polymorphic forms of avatrombopag maleate |
| CN112022825B (zh) * | 2020-08-24 | 2024-03-22 | 瑞阳制药股份有限公司 | 马来酸阿伐曲泊帕片剂及其制备方法 |
| CN112409350B (zh) * | 2020-11-27 | 2023-12-19 | 上海迪赛诺生物医药有限公司 | 一种马来酸阿伐曲泊帕晶型c的制备方法 |
| CN113185510B (zh) * | 2021-04-12 | 2022-05-13 | 南京海纳医药科技股份有限公司 | 一种阿伐曲泊帕杂质的制备方法 |
| WO2025132929A2 (en) | 2023-12-19 | 2025-06-26 | Synthon B.V | Salts of avatrombopag |
| WO2025133011A1 (en) | 2023-12-21 | 2025-06-26 | Synthon B.V | Formulation comprising form b of avatrombopag maleate |
| EP4660195A1 (en) | 2024-06-05 | 2025-12-10 | Noucor Health S.A. | Crystalline forms of avatrombopag maleate and preparation thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7638536B2 (en) | 2002-01-18 | 2009-12-29 | Astellas Pharma Inc. | 2-Acylaminothiazole derivative or salt thereof |
| AU2003268687A1 (en) | 2002-09-30 | 2004-04-19 | Yamanouchi Pharmaceutical Co., Ltd. | Novel salt of 2-acylaminothiazole derivative |
-
2011
- 2011-08-03 JP JP2011169730A patent/JP2014144916A/ja not_active Withdrawn
-
2012
- 2012-08-01 PL PL12759833T patent/PL2739621T3/pl unknown
- 2012-08-01 PL PL17176670T patent/PL3246325T3/pl unknown
- 2012-08-01 LT LTEP12759833.2T patent/LT2739621T/lt unknown
- 2012-08-01 ES ES12759833.2T patent/ES2636749T3/es active Active
- 2012-08-01 WO PCT/JP2012/004885 patent/WO2013018362A1/en not_active Ceased
- 2012-08-01 SI SI201231757T patent/SI3246325T1/sl unknown
- 2012-08-01 DK DK12759833.2T patent/DK2739621T3/da active
- 2012-08-01 RS RS20200374A patent/RS60358B1/sr unknown
- 2012-08-01 EP EP12759833.2A patent/EP2739621B1/en active Active
- 2012-08-01 HR HRP20171214TT patent/HRP20171214T1/hr unknown
- 2012-08-01 DK DK17176670.2T patent/DK3246325T3/da active
- 2012-08-01 LT LTEP17176670.2T patent/LT3246325T/lt unknown
- 2012-08-01 SM SM20200173T patent/SMT202000173T1/it unknown
- 2012-08-01 PT PT127598332T patent/PT2739621T/pt unknown
- 2012-08-01 SI SI201231023T patent/SI2739621T1/sl unknown
- 2012-08-01 ES ES17176670T patent/ES2784384T3/es active Active
- 2012-08-01 HU HUE12759833A patent/HUE034270T2/en unknown
- 2012-08-01 EP EP17176670.2A patent/EP3246325B1/en active Active
- 2012-08-01 PT PT171766702T patent/PT3246325T/pt unknown
-
2017
- 2017-08-09 CY CY171100854T patent/CY1120647T1/el unknown
-
2020
- 2020-04-03 HR HRP20200546TT patent/HRP20200546T1/hr unknown
- 2020-04-13 CY CY20201100344T patent/CY1122974T1/el unknown
- 2020-08-25 LT LTPA2020526C patent/LTC3246325I2/lt unknown
- 2020-09-14 NO NO2020032C patent/NO2020032I1/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2739621B1 (en) | 2017-06-21 |
| HRP20171214T1 (hr) | 2017-10-20 |
| PT3246325T (pt) | 2020-04-21 |
| JP2014144916A (ja) | 2014-08-14 |
| PL2739621T3 (pl) | 2017-12-29 |
| SMT202000173T1 (it) | 2020-05-08 |
| CY1120647T1 (el) | 2019-12-11 |
| ES2636749T3 (es) | 2017-10-09 |
| ES2784384T3 (es) | 2020-09-24 |
| PL3246325T3 (pl) | 2020-07-27 |
| WO2013018362A1 (en) | 2013-02-07 |
| RS60358B1 (sr) | 2020-07-31 |
| EP2739621A1 (en) | 2014-06-11 |
| NO2020032I1 (no) | 2020-09-14 |
| LTPA2020526I1 (lt) | 2020-09-25 |
| HRP20200546T1 (hr) | 2020-08-07 |
| PT2739621T (pt) | 2017-08-16 |
| DK3246325T3 (da) | 2020-04-20 |
| HK1246793A1 (en) | 2018-09-14 |
| LT3246325T (lt) | 2020-05-11 |
| LTC3246325I2 (lt) | 2023-11-10 |
| EP3246325B1 (en) | 2020-03-25 |
| SI2739621T1 (sl) | 2017-10-30 |
| SI3246325T1 (sl) | 2020-07-31 |
| CY1122974T1 (el) | 2021-10-29 |
| HUE034270T2 (en) | 2018-02-28 |
| LT2739621T (lt) | 2017-09-25 |
| EP3246325A1 (en) | 2017-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2739621B1 (en) | 2-acylaminothiazole compound crystals | |
| RU2672563C1 (ru) | Кристаллы 3,5-дизамещенного бензолалкинильного соединения | |
| US20170210760A1 (en) | Crystalline free bases of c-met inhibitor or crystalline acid salts thereof, and preparation methods and uses thereof | |
| JP2023175689A (ja) | 置換ピロロトリアジン系化合物およびその医薬組成物並びにそれらの使用 | |
| CN110092775B (zh) | 靶向cdk4/6激酶抑制剂的晶型 | |
| US12227536B2 (en) | Crystalline forms of an NRTTI compound | |
| CN105073740B (zh) | 一种化合物的盐及晶型或无定型物、其制备方法、含有它们的药物组合物和用途 | |
| CA2628630A1 (en) | Compositions of lipoxygenase inhibitors | |
| BRPI1012666B1 (pt) | cocristal de etravirina e nicotinamida, composição farmacêutica, combinação compreendendo o mesmo, seu processo para a preparação e uso | |
| CN104109124B (zh) | 卡博替尼·0.5苹果酸盐的晶体 | |
| CN108135877A (zh) | 药物共晶及其用途 | |
| TW201209041A (en) | New crystalline forms of N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-{[(1R,2S)-2,3-dihydroxy-1-methylpropyl]oxy}-4-pyrimidinyl]-1-azetidinesulfonamide | |
| WO2019190822A1 (en) | Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine | |
| CN107129502B (zh) | EOC315 Mod.I晶型化合物及其制备方法 | |
| JP2021512170A (ja) | Ｃｄｋ４／６キナーゼ阻害剤を標的とする結晶形 | |
| HK1246793B (en) | 2-acylaminothiazole compound crystals | |
| TWI664172B (zh) | 來那度胺的晶型及其製備方法和用途 | |
| JP7607596B2 (ja) | ３－（４－（ベンジルオキシ）フェニル）ヘキス－４－イノイック酸誘導体の新規結晶形 | |
| EP1896433A2 (en) | Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-yl)-n-pentanoyl-n-[2'-(1h-tetrazol-5-yl)bi-phenyl-4-ylmethyl]-amine | |
| CN102731430A (zh) | 非布司他的新晶型和其制备方法以及应用 | |
| JP7322151B2 (ja) | 医薬化合物、その製造方法、及び薬剤としての使用 | |
| KR100364941B1 (ko) | 1-[5-메탄설폰아미도인돌릴-2-카보닐]-4-[3-(1-메틸에틸아미노)-2-피리디닐]피페라진의신규한결정형태 | |
| KR20050059132A (ko) | 신규 결정 | |
| RU2853285C2 (ru) | Новые кристаллические формы соединения nrtti | |
| CN108003152B (zh) | 4-苯基-5-(1,2,4-三唑基)-2-吡啶氨基噻唑衍生物及其医药用途 |